C. Warren Olanow MD, FRCPC, FRCP (hon)
Clintrex Research Corp, Mount Sinai School of Medicine, New York City, New York, USA
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic
A disease modifying therapy for PD is the major unmet therapeutic need in this disorder. Despite the many promising targets and candidate therapies, many pharmaceutical companies are abandoning this field because of the development costs and regulatory uncertainties. The lecture describes a new approach that Dr. Olanow believes can overcome these problems.
- Be familiar with obstacles to development of a putative disease modifying therapy for PD
- Know the clinical designs that have been used to date to try and define a disease modifying therapy
- Appreciate a new approach to developing disease modifying therapies for PD
Movement disorder specialists, neurologists, individuals in the biotech and pharmaceutical industry who are potentially interested in developing disease modifying therapies for PD
This lecture will be made available for on-demand viewing starting on February 3, 2021.